An interventional study of Sleep intervention in Type 1 Diabetes, sponsored by University of Colorado, Denver. Enrolling by invitation at 1 site in United States. Open to participants aged 11 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-03-27.
Sponsored by University of Colorado, Denver · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies in Diabetes Mellitus, Type 1 by University of Colorado, Denver — 10 open to participants now, 13 under way, 1 of them phase 3. Diabetes Mellitus, Type 1 · University of Colorado, Denver.
Among the 58 studies in Diabetes Mellitus, Type 1 by University of Colorado, Denver, this one is the 18th largest by planned enrollment of the 44 interventional ones that give a count, is one of 3 that started in 2026, is one of 25 with no phase, reaches primary completion later than 4 of the 12 other live ones, and was the 57th registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →10 of the 58 studies in Diabetes Mellitus, Type 1 by University of Colorado, Denver are open now, in 1 country. Recruiting first, the newest first:
University of Colorado, Denver · Sites in United States
Ages 10–20
University of Colorado, Denver · Sites in United States
Ages 18–89
University of Colorado, Denver · Sites in United States
Ages 14–19
University of Colorado, Denver · Sites in United States
Ages 14–26
University of Colorado, Denver · Sites in United States
Ages 2–26
By country, each count listing its studies:
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 11 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
58 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 3 · Phase 4 8
First in 1993; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is above the median of 40 across 2,824 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 44 across the 44 interventional studies, 85 across the 14 observational. Of the 43 that completed or were terminated, 19 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Colorado, Denver is the lead sponsor of 1,547 studies on the registry; 318 are open to participants now.
Of its 148 completed or terminated interventional studies of FDA-regulated products, 93 (63%) have results posted.
6 of the studies in Diabetes Mellitus, Type 1 by University of Colorado, Denver that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05819138Phase 3University of Colorado, DenverType 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes | 2027-10-01 |
| NCT07494188University of Colorado, DenverSleep Screening and Intervention for Adolescents With Type 1 Diabetes in a Clinical Diabetes Center | 2026-12-01 |
| NCT07011147University of Colorado, DenverPrimary Care Pragmatic, Real World Experience for Automated Insulin Delivery | 2027-06-30 |
| NCT05319990University of Colorado, DenverPathogenesis of Kidney Disease in Type 1 Diabetes: a Modern Kidney Biopsy Cohort (The PANDA Study) | 2027-06-30 |
| NCT07720388University of Colorado, DenverSupporting Medtronic 780G Insulin Pump Adoption in Latino Patients: A Spanish - Language Training Initiative | 2027-07 |
Add all 6 to your calendar (.ics) → With an account.
Among the 58 studies in Diabetes Mellitus, Type 1 by University of Colorado, Denver, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is evaluating an in-clinic sleep screening and intervention algorithm for youth with type 1 diabetes. This study will assess health care provider feasibility of completion of intervention and long term follow up for adolescents with T1D.
This study involves enrollment of adolescents with T1D in conjunction with a diabetes health care provider at the Barbara Davis Center. Adolescents will complete a sleep screening questionnaire prior to the clinic visit. If the adolescent screens positive for sleep concerns, they will complete an indepth questionnaire to identify the barriers to sleep and this information will be provided to the health care provider. During the routine T1D clinic visit, the health care provider will be provided with the questionnaire answers and sleep interventions, and will address these at their discretion throughout the clinical encounter. Adolescents enrolled in the study will be follow at 3 months. For those that screened positive for sleep concerns, questionnaires will be completed related to the intervention to determine completion, retention, and follow through. Those who did not screen positive, will additionally complete a follow up sleep screener to assess consistency in their sleep health.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
All adolescents enrolled will complete the sleep screening questionnaire
Behavioral: Sleep intervention
Adolescents that screen positive for sleep concerns will receive targeted interventions based on their self-reported sleep barriers. These will be provided by the health care provider.
Intervention Completion Rate
Assess the feasibility/rate of completion of sleep intervention discussion within the clinic session based on the percent of interventions completed for those who screened positive in the sleep screening.
Time frame: Day 1
Plan to share: Undecided — Data sharing can be made available upon request on a case by case basis
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Dec 2026, 9 months after the start.
Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 9 months is below that.
Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Colorado, Denver →